Suppr超能文献

丙型肝炎病毒与甲型肝炎病毒RNA复制的比较分析揭示了甲型肝炎病毒治疗的新视角。

Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replication.

作者信息

Esser-Nobis Katharina, Harak Christian, Schult Philipp, Kusov Yuri, Lohmann Volker

机构信息

Department of Infectious Diseases, Molecular Virology, University of Heidelberg, Germany.

Institute of Biochemistry, Center for Structural and Cell Biology in Medicine and German Center for Infection Research (DZIF), University of Lübeck, Germany.

出版信息

Hepatology. 2015 Aug;62(2):397-408. doi: 10.1002/hep.27847. Epub 2015 May 20.

Abstract

UNLABELLED

Hepatitis A virus (HAV) and hepatitis C virus (HCV) are two positive-strand RNA viruses sharing a similar biology, but causing opposing infection outcomes, with HAV always being cleared and HCV establishing persistence in the majority of infections. To gain deeper insight into determinants of replication, persistence, and treatment, we established a homogenous cell-culture model allowing a thorough comparison of RNA replication of both viruses. By screening different human liver-derived cell lines with subgenomic reporter replicons of HAV as well as of different HCV genotypes, we found that Huh7-Lunet cells supported HAV- and HCV-RNA replication with similar efficiency and limited interference between both replicases. HAV and HCV replicons were similarly sensitive to interferon (IFN), but differed in their ability to establish persistent replication in cell culture. In contrast to HCV, HAV replicated independently from microRNA-122 and phosphatidylinositol 4-kinase IIIα and β (PI4KIII). Both viruses were efficiently inhibited by cyclosporin A and NIM811, a nonimmunosuppressive analog thereof, suggesting an overlapping dependency on cyclophilins for replication. However, analysis of a broader set of inhibitors revealed that, in contrast to HCV, HAV does not depend on cyclophilin A, but rather on adenosine-triphosphate-binding cassette transporters and FK506-binding proteins. Finally, silibinin, but not its modified intravenous formulation, efficiently inhibited HAV genome replication in vitro, suggesting oral silibinin as a potential therapeutic option for HAV infections.

CONCLUSION

We established a cell-culture model enabling comparative studies on RNA replication of HAV and HCV in a homogenous cellular background with comparable replication efficiency. We thereby identified new host cell targets and potential treatment options for HAV and set the ground for future studies to unravel determinants of clearance and persistence.

摘要

未标记

甲型肝炎病毒(HAV)和丙型肝炎病毒(HCV)是两种正链RNA病毒,具有相似的生物学特性,但导致相反的感染结果,HAV总是被清除,而HCV在大多数感染中会持续存在。为了更深入了解复制、持续存在和治疗的决定因素,我们建立了一个同质细胞培养模型,以便对两种病毒的RNA复制进行全面比较。通过用HAV的亚基因组报告复制子以及不同HCV基因型筛选不同的人肝源细胞系,我们发现Huh7-Lunet细胞以相似的效率支持HAV和HCV-RNA复制,并且两种复制酶之间的干扰有限。HAV和HCV复制子对干扰素(IFN)同样敏感,但在细胞培养中建立持续复制的能力有所不同。与HCV不同,HAV独立于微小RNA-122和磷脂酰肌醇4-激酶IIIα和β(PI4KIII)进行复制。两种病毒都被环孢素A及其非免疫抑制类似物NIM811有效抑制,这表明复制对亲环蛋白有重叠依赖性。然而,对更广泛的一组抑制剂的分析表明,与HCV不同,HAV不依赖亲环蛋白A,而是依赖三磷酸腺苷结合盒转运蛋白和FK506结合蛋白。最后,水飞蓟宾而非其改良的静脉制剂在体外有效抑制HAV基因组复制,这表明口服水飞蓟宾可能是治疗HAV感染的潜在选择。

结论

我们建立了一个细胞培养模型,能够在同质细胞背景下以可比的复制效率对HAV和HCV的RNA复制进行比较研究。我们由此确定了HAV的新宿主细胞靶点和潜在治疗选择,并为未来研究揭示清除和持续存在的决定因素奠定了基础。

相似文献

6
The JAK2 inhibitor AZD1480 inhibits hepatitis A virus replication in Huh7 cells.JAK2抑制剂AZD1480可抑制甲型肝炎病毒在Huh7细胞中的复制。
Biochem Biophys Res Commun. 2015 Mar 20;458(4):908-12. doi: 10.1016/j.bbrc.2015.02.058. Epub 2015 Feb 19.

引用本文的文献

5
Masitinib Inhibits Hepatitis A Virus Replication.马替尼抑制甲型肝炎病毒复制。
Int J Mol Sci. 2023 Jun 3;24(11):9708. doi: 10.3390/ijms24119708.
10
Picornaviruses: A View from 3A.小核糖核酸病毒:从 3A 视角看
Viruses. 2021 Mar 11;13(3):456. doi: 10.3390/v13030456.

本文引用的文献

2
Hepatitis A virus and the origins of picornaviruses.甲型肝炎病毒与小核糖核酸病毒的起源
Nature. 2015 Jan 1;517(7532):85-88. doi: 10.1038/nature13806. Epub 2014 Oct 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验